{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Precipio, Inc.
Precipio, Inc. Hits New 52-Week High of $27.29, Up 356.52%
Precipio, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, achieved a new 52-week high of USD 27.29 on November 19, 2025, reflecting a substantial year-over-year gain. Despite its current losses and competitive challenges, the milestone highlights the company's notable market activity and performance.
Is Precipio, Inc. overvalued or undervalued?
As of October 1, 2023, Precipio, Inc. is fairly valued with a price-to-earnings ratio of 15.2, competitive against peers, and has shown resilient stock performance aligned with market trends.
Is Precipio, Inc. technically bullish or bearish?
As of October 1, 2023, there is insufficient technical data for Precipio, Inc. to determine a bullish or bearish outlook.
Who are in the management team of Precipio, Inc.?
As of March 2022, the management team of Precipio, Inc. includes Dr. Douglas Fisher (Interim Chairman), Mr. Ilan Danieli (CEO), and several directors, including Mr. David Cohen, Mr. Mark Rimer, Dr. Jeffrey Cossman, Ms. Kathleen LaPorte, and Mr. Richard Sandberg. They are responsible for the company's strategic direction and operations.
What does Precipio, Inc. do?
Precipio, Inc. is a micro-cap cancer diagnostics company that offers products and services for the oncology market, with recent net sales of $5 million and a net loss of $1 million. The company has a market cap of $16.78 million and operates with a negative return on equity of -26.46%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
